MedTrace Logo

Pharmacokinetics and Dynamics of Dexmedetomidine as Adjuvant in TAP Block

NCT03328299 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2020-10-22

No results posted yet for this study

Summary

TAP-block has been shown to be a safe and effective postoperative analgesia method in a variety of general. Dexmedetomidine is a selective α2 agonist with 8 times more affinity for α2 adrenergic receptors compared to clonidine and possesses all the properties of α2 agonist without respiratory depression. Dexmedetomidine has been focus of interest for its broad spectrum (sedative, analgesic and anesthetic sparing) properties, making it a useful and safe adjunct in many clinical applications.

Conditions

  • Postoperative Pain

Interventions

DRUG

Dexmedetomidine

20 ml of 0.5 % bupivacaine plus dexmedetomidine 1 μg•kg-1

DRUG

bupivacaine

20 ml of 0.5 % bupivacaine

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-11
Primary Completion
2018-12-01
Completion
2019-09-01
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03328299 on ClinicalTrials.gov